Skip Nav Destination
Issues
1 December 2012
-
Cover Image
Cover Image
Olfactomedin-like 3 (Olfml3), a proangiogenic cue and a BMP4 agonist, is produced by both tumor endothelial cells and accompanying pericytes and deposited in the perivascular compartment. Blocking Olfml3 regresses the tumor vasculature, decreases pericyte coverage, and inhibits the progression of tumors. Olfml3 blockade provides an alternative strategy to control tumor growth by targeting a single molecule that affects two distinct cell types within the tumor microenvironment. For details, see article by Miljkovic-Licina and colleagues on page 2588. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Therapeutic Discovery
Dll4-Fc, an Inhibitor of Dll4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity
Takuya Kuramoto; Hisatsugu Goto; Atsushi Mitsuhashi; Sho Tabata; Hirohisa Ogawa; Hisanori Uehara; Atsuro Saijo; Soji Kakiuchi; Yoichi Maekawa; Koji Yasutomo; Masaki Hanibuchi; Shin-ichi Akiyama; Saburo Sone; Yasuhiko Nishioka
RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma
Yuji Shimura; Junya Kuroda; Masaki Ri; Hisao Nagoshi; Mio Yamamoto-Sugitani; Tsutomu Kobayashi; Miki Kiyota; Ryuko Nakayama; Shinsuke Mizutani; Yoshiaki Chinen; Natsumi Sakamoto; Yosuke Matsumoto; Shigeo Horiike; Yukimasa Shiotsu; Shinsuke Iida; Masafumi Taniwaki
Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Ping Yi; Arisa Higa; Said Taouji; Mariana G. Bexiga; Esther Marza; Daniela Arma; Claire Castain; Brigitte Le Bail; Jeremy C. Simpson; Jean Rosenbaum; Charles Balabaud; Paulette Bioulac-Sage; Jean-Frédéric Blanc; Eric Chevet
Preclinical Development
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
Matthias Friedrich; Tobias Raum; Ralf Lutterbuese; Markus Voelkel; Petra Deegen; Doris Rau; Roman Kischel; Patrick Hoffmann; Christian Brandl; Joachim Schuhmacher; Peter Mueller; Ricarda Finnern; Melanie Fuergut; Dieter Zopf; Jerry W. Slootstra; Patrick A. Baeuerle; Benno Rattel; Peter Kufer
Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
Michelle K. Gleason; Michael R. Verneris; Deborah A. Todhunter; Bin Zhang; Valarie McCullar; Sophia X. Zhou; Angela Panoskaltsis-Mortari; Louis M. Weiner; Daniel A. Vallera; Jeffrey S. Miller
Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts
Angela Romanelli; Anderson Clark; Franck Assayag; Sophie Chateau-Joubert; Marie-France Poupon; Jean-Luc Servely; Jean-Jacques Fontaine; Xiaohong Liu; Edward Spooner; Samantha Goodstal; Patricia de Cremoux; Ivan Bièche; Didier Decaudin; Elisabetta Marangoni
Spotlight on Clinical Response
Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
James S. Wilmott; Varsha Tembe; Julie R. Howle; Raghwa Sharma; John F. Thompson; Helen Rizos; Roger S. Lo; Richard F. Kefford; Richard A. Scolyer; Georgina V. Long
Reviewers
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.